References
1. Balasubramanian P., Kiss T., Tarantini S., et al. Obesity-induced cognitive impairment in older adults: a microvascular perspective. Am J Physiol Heart Circ Physiol. 2021; 320 (2): H740–61.
2. Zonneveld M.H., Noordam R., van der Grond J., et al. Interplay of circulating leptin and obesity in cognition and cerebral volumes in older adults. Peptides. 2021; 135: 170424.
3. Lee T.H., Yau S.Y. From obesity to hippocampal neurodegeneration: pathogenesis and non-pharmacological interventions. Int J Mol Sci. 2020; 22 (1): 201.
4. Kivipelto M., Mangialasche F., Ngandu T. Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease. Nat Rev Neurol. 2018; 14 (11): 653–66.
5. Yaribeygi H., Rashidy-Pour A., Atkin S.L., et al. GLP-1 mimetics and cognition. Life Sci. 2021; 264: 118645. DOI: https://doi.org/10.1016/j.lfs.2020.118645
6. Dye L., Boyle N.B., Champ C., et al., The relationship between obesity and cognitive health and decline. Proc Nutr Soc. 2017; 76 (4): 443–54.
7. Bassil F., Fernagut P.O., Bezard E., et al. Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification? Prog Neurobiol. 2014; 118: 1–18.
8. Grieco M., Giorgi A., Gentile M.C., et al. Glucagon-like peptide-1: a focus on neurodegenerative diseases. Front Neurosci. 2019; 13: 1112.
9. Yildirim Simsir I., Soyaltin U.E., Cetinkalp S. Glucagon like peptide-1 (GLP-1) likes Alzheimer’s disease. Diabetes Metab Syndr. 2018; 12 (3): 469–75.
10. Femminella G.D., Frangou E., Love S.B., et al. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study). Trials. 2019; 20 (1): 191.
11. Mansur R.B., Lee Y., Subramaniapillai M., Brietzke E., et al. Cognitive dysfunction and metabolic comorbidities in mood disorders: a repurposing opportunity for glucagon-like peptide 1 receptor agonists? Neuropharmacology. 2018; 136 (pt B): 335–42.
12. Li P.C., Liu L.F., Jou M.J., et al. The GLP-1 receptor agonists exendin-4 and liraglutide alleviate oxidative stress and cognitive and micturition deficits induced by middle cerebral artery occlusion in diabetic mice. BMC Neurosci. 2016; 17 (1): 37.
13. Holscher C. Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer’s disease. Recent Pat CNS Drug Discov. 2010; 5 (2): 109–17.
14. Porter D.W., Kerr B.D., Flatt P.R., et al. Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance. Diabetes Obes Metab. 2010; 12 (10): 891–9.
15. Carranza-Naval M.J., Del Marco A., Hierro-Bujalance C., et al. Liraglutide reduces vascular damage, neuronal loss, and cognitive impairment in a mixed murine model of Alzheimer’s disease and type 2 diabetes. Front Aging Neurosci. 2021; 13:741923.